Johnson & Johnson Delivers on Multibillion-Dollar US Manufacturing and Innovation Investments
Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion US investment.
Johnson & Johnson continues to deliver on its previously announced $55 billion investment to support US manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the company has initiated billions of dollars in investment in US manufacturing, which will support its goal of manufacturing the vast majority of its advanced medicines in the US to meet the needs of US patients.
As part of the $55 billion investment, Johnson & Johnson announced two new US manufacturing facilities, including a next-generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.
Additionally, construction is progressing on its $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which broke ground last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.
In September, the company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.
Johnson & Johnson expects to announce additional US investments later this year.
